Vertex Pharmaceuticals Incorporated VRTX
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) EV/Sales
As of 25 September 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a EV/Sales of 10.0×. Over the past ten years it has ranged from 5.5× (October 2021) to 53.8× (August 2015); the current reading is higher than 41% of that period. That is below the Biotechnology industry median of 10.7× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 9.1× | 2.68% |
| FY2024 | 8.9× | (7.80%) |
| FY2023 | 9.6× | 36.67% |
| FY2022 | 7.1× | 7.59% |
| FY2021 | 6.6× | (26.48%) |
| FY2020 | 8.9× | (29.95%) |
| FY2019 | 12.7× | (2.66%) |
| FY2018 | 13.1× | (11.68%) |
| FY2017 | 14.8× | 42.69% |
| FY2016 | 10.4× | (64.36%) |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 9.4× | 7.97% |
| Mar 2026 | 8.7× | (4.55%) |
| Dec 2025 | 9.1× | 13.79% |
| Sep 2025 | 8.0× | (15.29%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | 4.9× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.0× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.6× |
| VRTX Vertex Pharmaceuticals Incorporated | 10.0× |
| ARGX argenex SE compare | 10.5× |
| RPRX Royalty Pharma PLC compare | 13.4× |
| INSM Insmed, Inc. compare | 22.2× |
| MRNA Moderna, Inc. compare | 33.5× |
| RVMD Revolution Medicines, Inc. compare | 1,499× |
| Biotechnology industry median | 10.7× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement